TY  - JOUR
T1  - First Report of Escherichia coli Sequence Type 1193 a Multidrug-Resistant Clone Isolated in Ha'il, Saudi Arabia
A1  - Mohammed Suliman AlMogbel
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2022
VL  - 11
IS  - 2
DO  - 10.51847/yc7clmEGmi
SP  - 24
EP  - 28
N2  - Escherichia coli is a significant source of morbidity and mortality in humans due to their enhanced virulence and colonization capacities, which enable them to cause a range of extraintestinal manifestations, including wound infection, neonatal meningitis, urosepsis, and urinary tract infection. In the recent past, globally, fluoroquinolone-resistant (FQr) E. coli sequence type ST1193 has emerged as a major causative agent of E. coli infections in humans. Here, we present a case report of a 54-year-old male who was presented with urethral strictures as well as an overactive bladder (OAB). The patient got a recurrent urinary tract infection (UTI) five times (during the timespan from 31/12/2018 to 18/06/2019). The causative agent was identified as extended-spectrum beta-lactamase (ESBL) positive; AmpC beta-lactamase positive, and ciprofloxacin-resistant E. coli ST1193. This is the first case of recurrent UTI caused by ESBL & AmpC beta-lactamase generating ST1193 E. coli in Ha'il, Saudi Arabia, to our knowledge. The ST1193 ESBL-producing E. coli isolates cultured in this study were resistant to ciprofloxacin and belonged to serogroup H5. Further regional studies are needed to assess the relevance of ESBL-producing E. coli ST1193 which could turn into a nosocomial pathogen in Saudi Arabia. For this recently emerged E. coli ST1193 clone, strategic surveillance, and control techniques will be required in the future. 
UR  - https://ijpras.com/article/first-report-of-escherichia-coli-sequence-type-1193-a-multidrug-resistant-clone-isolated-in-hail-s-odrvhjp26dclyjn
ER  -